AR
MRNA icon

Advisory Research’s Moderna MRNA Stock Holding History

Advisory Research’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,935
Closed -$999K – 424
2021
Q4 		$999K Buy
3,935
+1,363
+53% +$399K 0.08% 196
2021
Q3 		$990K Sell
2,572
-5,972
-70% -$2.2M 0.06% 201
2021
Q2 		$2.01M Sell
8,544
-3,182
-27% -$569K 0.13% 136
2021
Q1 		$1.54M Buy
11,726
+2,807
+31% +$407K 0.11% 156
2020
Q4 		$932K Sell
8,919
-5,956
-40% -$603K 0.07% 200
2020
Q3 		$1.05M Sell
14,875
-4,840
-25% -$337K 0.1% 171
2020
Q2 		$1.27M Sell
19,715
-5,250
-21% -$288K 0.11% 146
2020
Q1 		$748K Sell
24,965
-13,957
-36% -$321K 0.05% 155
2019
Q4 		$761K Buy
38,922
+19,725
+103% +$350K 0.04% 201
2019
Q3 		$306K Buy
+19,197
New +$284K 0.01% 290

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisory Research's MRNA Position: Q1 2022 in Review

Advisory Research sold out of Moderna (MRNA) in Q1 2022, closing a stake of 3,935 shares — an estimated $999K sold.

Advisory Research first reported a position in MRNA in Q3 2019 and held it in 10 quarters. The position peaked at $2.01M in Q2 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Advisory Research reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Advisory Research sold 3,935 Moderna shares in Q1 2022, an estimated $999K.
  • Advisory Research first reported a position in Moderna in Q3 2019 and held it in 10 quarters.
  • Advisory Research's Moderna position peaked at $2.01M in Q2 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Advisory Research's 13F filing for Q1 2022, filed 16 May 2022.